Favourable prognostic role of regression of primary melanoma in AJCC stage I–II patients. (December 2013)
- Record Type:
- Journal Article
- Title:
- Favourable prognostic role of regression of primary melanoma in AJCC stage I–II patients. (December 2013)
- Main Title:
- Favourable prognostic role of regression of primary melanoma in AJCC stage I–II patients
- Authors:
- Ribero, S.
Osella‐Abate, S.
Sanlorenzo, M.
Savoia, P.
Astrua, C.
Cavaliere, G.
Tomasini, C.
Senetta, R.
Macripò, G.
Bernengo, M.G.
Quaglino, P. - Abstract:
- <abstract abstract-type="main" id="bjd12586-abs-0001"> <title>Summary</title> <sec id="bjd12586-sec-0001" sec-type="section"> <title>Background</title> <p>The prognostic significance of regression in primary melanoma has been debated over the past few years. Once it was considered to be a negative prognostic factor, as it may have prevented proper melanoma thickness measurement, therefore affecting the staging of the tumours. For this reason, it was considered to be an indication for sentinel lymph node biopsy (SLNB) in melanoma &lt; 1 mm.</p> </sec> <sec id="bjd12586-sec-0002" sec-type="section"> <title>Objectives</title> <p>To ascertain the utility of SLNB in thin melanoma and to clarify the role of regression in disease‐free survival (DFS) and overall survival (OS) in our series.</p> </sec> <sec id="bjd12586-sec-0003" sec-type="section"> <title>Methods</title> <p>We analysed data collected from 1693 consecutive patients with AJCC (American Joint Committee on Cancer) stage I–II melanoma.</p> </sec> <sec id="bjd12586-sec-0004" sec-type="section"> <title>Results</title> <p>Globally, SLNB was performed in 656 out of 1693 patients. Regression was present in 349 patients and 223 of them were characterized by thin lesions. SLNB was performed in 104 cases of thin melanoma with regression. The majority of regional lymph node metastases were observed in patients who did not undergo SLNB (89 out of 132). Among the remaining 43 'false negative' patients only three showed regression<abstract abstract-type="main" id="bjd12586-abs-0001"> <title>Summary</title> <sec id="bjd12586-sec-0001" sec-type="section"> <title>Background</title> <p>The prognostic significance of regression in primary melanoma has been debated over the past few years. Once it was considered to be a negative prognostic factor, as it may have prevented proper melanoma thickness measurement, therefore affecting the staging of the tumours. For this reason, it was considered to be an indication for sentinel lymph node biopsy (SLNB) in melanoma &lt; 1 mm.</p> </sec> <sec id="bjd12586-sec-0002" sec-type="section"> <title>Objectives</title> <p>To ascertain the utility of SLNB in thin melanoma and to clarify the role of regression in disease‐free survival (DFS) and overall survival (OS) in our series.</p> </sec> <sec id="bjd12586-sec-0003" sec-type="section"> <title>Methods</title> <p>We analysed data collected from 1693 consecutive patients with AJCC (American Joint Committee on Cancer) stage I–II melanoma.</p> </sec> <sec id="bjd12586-sec-0004" sec-type="section"> <title>Results</title> <p>Globally, SLNB was performed in 656 out of 1693 patients. Regression was present in 349 patients and 223 of them were characterized by thin lesions. SLNB was performed in 104 cases of thin melanoma with regression. The majority of regional lymph node metastases were observed in patients who did not undergo SLNB (89 out of 132). Among the remaining 43 'false negative' patients only three showed regression in the primary. Using the Cox multivariate model, histological regression maintained a significant protective role [hazard ratio (HR) 0·62, <italic>P </italic>=<italic> </italic>0·012 for DFS; HR 0·43, <italic>P </italic>=<italic> </italic>0·008 for OS] when corrected for the principal histopathological and clinical features, despite SLNB.</p> </sec> <sec id="bjd12586-sec-0005" sec-type="section"> <title>Conclusions</title> <p>We confirmed that regression alone should not be a reason to perform SLNB in thin melanoma and, on the contrary, it can be considered a favourable prognostic factor in patients with AJCC stage I–II melanoma.</p> </sec> </abstract> … (more)
- Is Part Of:
- British journal of dermatology. Volume 169:Number 6(2013:Dec.)
- Journal:
- British journal of dermatology
- Issue:
- Volume 169:Number 6(2013:Dec.)
- Issue Display:
- Volume 169, Issue 6 (2013)
- Year:
- 2013
- Volume:
- 169
- Issue:
- 6
- Issue Sort Value:
- 2013-0169-0006-0000
- Page Start:
- 1240
- Page End:
- 1245
- Publication Date:
- 2013-12
- Subjects:
- Dermatology -- Periodicals
Skin -- Diseases -- Periodicals
616.5 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1365-2133 ↗
https://academic.oup.com/bjd ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/bjd.12586 ↗
- Languages:
- English
- ISSNs:
- 0007-0963
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 2307.400000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 4328.xml